Diabetes Professional Resources Online  /  American Diabetes Association
Home About Us Donate Now Join ADA
DiabetesPro Home
Meetings and Continuing Education Opportunities
Scientific Sessions Webcasts
Resources for Professionals
Clinical Practice
Recommendations
Professional Membership
Journals
Books for Professionals
Research Grant Applications and Administration
About Diabetes Research
Recognition Programs
Professional Section
Interest Groups
Professional Section
Quarterly
Thomson Reuters - Prous Science
 
Print this page Email this article
Click on - or + to modify the size of the text on this page. Decrease Font Size Increase Font Size

Click to add/remove this article to your list of 'My Favorites'
Corneal Nerve Morphology: A Surrogate Marker for Human Diabetic Neuropathy Improves with Improved Glycaemic Control

Year: 2005
Abstract Number: 871-P
Authors: ABID IQBAL, PANOS KALLINIKOS, NATHAN EFRON, ANDREW J. M. BOULTON, RAYAZ A. MALIK
Institutions: Manchester, United Kingdom

Results: Corneal confocal microscopy (CCFM) is a rapid, non-invasive technique which quantifies corneal nerve damage and has been shown to act as a reliable surrogate measure of somatic neuropathy in diabetic patients. To further validate this technique corneal nerve morphology (nerve fibre density (NFD) (no.mm2), branch density (NFBD) (no.mm2), length (NFL) (μm) and tortuosity (NFT)), was compared in 25 diabetic patients with mild to moderate neuropathy evaluated using the Neuropathy Impairment Score (NIS) and Vibration perception threshold (VPT) and eighteen control subjects at baseline and repeated in the diabetic patients 24 + 1.6 months later. NFD: 18.64±2.09 v 44.48±3.34, p=0.001, NBD: 7.23±1.52 v 78.90±7.16, p<0.0001, NFL: 8.28±0.54 v 13.47±0.80, p<0.0001 were significantly reduced in diabetic patients with no difference in NFT: 20.38±1.6643 v 20.35±1.65, p=0.991. In the diabetic patients between the baseline and follow up scan, corneal nerve morphology improved significantly (NFD (23.53±2.03,P=0.03), NBD (11.13±1.31, P=0.06), NFT (23.22±1.53,P=0.02) with no change in NFL (8.41±0.54, P=0.67). During this period HbA1c (8.1±0.31 to 7.5±0.23, p=0.08), total cholesterol (4.86±0.18 to 4.21±0.19 p=0.01), systolic BP (145.8±4.9 to 135.9±3.7, p =0.09) and diastolic BP (77.8±2.7 to 70.8±2.5, p = 0.03) improved with no significant change in triglycerides (1.75±0.21 to 1.49±0.22 p=0.17) or HDL (1.36±0.07 to 1.34±0.09, p=0.64). The improvement in NFD correlated significantly with the improvement in HbA1c (r=-0.52, p=0.008) but not with total cholesterol (r=-0.32, p=0.12), systolic (r=-0.20, p=0.34) or diastolic (r=-0.02, p=0.91) BP. CCFM appears to be a reliable surrogate marker for the diagnosis of human diabetic neuropathy. Furthermore it provides a future means of assessing therapeutic efficacy in clinical interventon trials, as an improvement in corneal nerve morphology was related to improved glycaemic control.

Category: Complications - Neuropathy